Cardiac magnetic resonance in Pompe disease: a systematic literature review

Amalia Lupi1, Elisa Schiavone1, Vincenza Gragnaniello2

  • 1Department of Medicine - DIMED, Institute of Radiology, University of Padua, Padua, Italy.

La Radiologia Medica
|April 25, 2026
PubMed

Insights

Cardiovascular magnetic resonance (CMR) in Pompe disease (PD) reveals limited data on cardiac involvement. Further research using advanced mapping techniques is needed to fully understand heart issues in PD patients.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Imaging

Background:

  • Pompe disease (PD) is a rare genetic disorder caused by acid alpha-glucosidase deficiency, leading to glycogen buildup in muscles, including the heart.
  • The extent and characteristics of cardiac involvement in both infantile (IOPD) and late-onset (LOPD) forms of PD remain unclear.
  • Cardiovascular magnetic resonance (CMR) offers potential for detecting cardiac alterations in PD patients.

Purpose of the Study:

  • To systematically review the existing literature on Cardiovascular Magnetic Resonance (CMR) features in Pompe disease (PD).
  • To identify and synthesize current knowledge on myocardial involvement in both IOPD and LOPD.

Main Methods:

  • A systematic search of PubMed, Scopus, and Web of Science databases was conducted up to February 2024.
  • Eleven studies were included after screening 276 articles, with data extraction and synthesis performed by two independent reviewers.
  • Included studies were graded using the Oxford Centre for Evidence Based Medicine (CEBM) system.

Main Results:

  • Seven studies focused on IOPD and four on LOPD.
  • Six studies reported late-gadolinium enhancement, one described TIRM sequence findings for cardiac infiltration, and three assessed Extracellular Volume changes.
  • Two studies utilized T1/T2 mapping and perfusion imaging, with one evaluating therapy response via T1 mapping.

Conclusions:

  • Current literature on CMR findings in Pompe disease is sparse and primarily relies on qualitative assessments.
  • Advanced imaging techniques, including mapping, are necessary for a comprehensive understanding of cardiac involvement in PD.
  • Further research is essential to elucidate the role of CMR in managing PD patients with cardiac manifestations.

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
936
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
786
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
813
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
746
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
550